July 9, 2018 -ABSTRACT
Outpatient-based sharp debridement is considered an important element for the care of a chronic ulcer.
Objective:The aim of this study is to evaluate the change in bacterial amounts with sharp debridement in a clinical setting.
Materials and Methods:Bacterial autofluorescence, quantitative cultures, semiquantitative cultures, and qualitative
… Read MoreJune 1, 2018 -ABSTRACT Aim:
Current gold standard technique for tissue management in DFUs is regular sharp debridement to reduce bioburden, as this optimizes effectiveness of antimicrobials and stimulates wound healing.1 However, the extent of debridement required to reduce bioburden based on visual inspection is unclear. Fluorescence imaging has recently been used
… Read MoreMay 10, 2018 -Without real-time confirmation of the presence and spatial distribution of bacterial burden within and around a wound, clinicians are at risk of making inappropriate and ineffective treatment decisions. Read More
May 1, 2018 -Clinical Synopsis
Patient Condition: 57 year old male patient delayed seeking treatment for a diabetic foot ulcer on his left toe for more than 2 months. Some challenges with this wound included rapid callus build-up, improper footwear, delayed treatment, and a lack of offloading.
This patient treated their diabetic foot ulcer with an over-the-counter antibiotic ointment for
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2026
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.